


Long-term Outcomes after I¹²⁵
Monotherapy for Localised
Prostate Cancer: Results from a
large single centre series.



Dr Ann Henry
Consultant Clinical Oncologist
Cookridge Hospital, Leeds, UK



Aims

- To report clinical outcomes in patients with at least 2 years FU after I¹²⁵ brachytherapy alone for localised prostate cancer
- To analyse impact of prognostic and other factors on clinical outcomes



Methods

- Time period March 1995 to September 2004
- 145 Gray (TG 43) delivered using I¹²⁵
- Monotherapy only
- Outcome data (biochemical failure, clinical relapse and survival) collected prospectively
- Modified ASTRO definition of biochemical failure (PSA bounce excluded), stratified into low, intermediate and high risk groups
- K-M survival and multivariate analysis



Results

- Total number of patients: 1298
- Mean age 62.9 yrs Range 34-83 yrs
- Follow-up
 - Median 4.9 years
 - Range 2.03 to 11.7 years
- Neo-adjuvant hormones in 44.2%



Patient characteristics

Presenting PSA	≤ 10	811 (62.5%)
	10-20	320 (24.6%)
	> 20	54 (4.2%)
	Unknown	113 (8.7%)
Gleason score	≤ 6	850 (65.5%)
	7	341 (26.3%)
	≥ 8	107 (8.2%)
TNM stage	T1a-T2a	725 (55.9%)
	T2b-T2c	179 (15.2%)
	≥ T3	2 (0.2%)
	Unknown	392 (30.2%)




Overall outcomes

Total number of patients	1298
ASTRO Biochemical relapse	192 (15%)
Clinical Relapse	74 (6%)
Prostate Cancer Deaths	21 (2%)
Deaths from other causes	33 (3%)
Lost to follow up	78 (6%)


Disease specific survival

10 yr DSS 95%




Overall survival

10 yr OS 85%




PSA Relapse-Free Survival

10 yr PSA-RFS 80%



PSA-RFS by presenting PSA


10 yr PSA-RFS:	
PSA ≤10	83%
PSA 10-20	73%
PSA > 20	49%



P < 0.01


PSA-RFS by Risk Group

10 yr PSA-RFS:	
Low	86%
Intermed	77%
High	61%



PSA-RFS and initial hormones

10 yr PSA-RFS:
No hormones
86%
Hormones
72%



	Number	FU (yrs)	Biochem control (%)	DSS (%)	OS (%)
Stock 2006	1377	10	87		
Potters 2005	1449	12	81	93	81
Merrick 2006	938	10	95.9	96.4	78.1
JHopkins (RRP)		10	70	96	
Leeds 2006	<i>1298</i>	<i>10</i>	<i>80</i>	<i>95</i>	<i>85</i>



Conclusions

- * I¹²⁵ monotherapy achieves excellent PSA control in low and intermediate risk groups, at 86% and 77% respectively at 10 years
- * On multivariate analysis, prognostic risk group and the use of neo-adjuvant hormones impact on long term PSA-RFS

Acknowledgements

- Dr Bashar Al-Qaisieh
- Dr Dan Ash
- Dr David Bottomley
- Dr Brendan Carey
- Kathy Gould
- Shaun St-Clair
- Liz St-Clair
- Theatre Staff

